Carrier Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (Expanded Carrier Screening v/s Targeted Cancer Screening), By Screening Type (Prenatal Carrier Testing v/s Preconception Carrier Screening), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Microarrays, Others), By Indication (Cystic Fibrosis, Down’s Syndrome
Published on: 2024-11-22 | No of Pages : 320 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Carrier Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (Expanded Carrier Screening v/s Targeted Cancer Screening), By Screening Type (Prenatal Carrier Testing v/s Preconception Carrier Screening), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Microarrays, Others), By Indication (Cystic Fibrosis, Down’s Syndrome
The global carrier screening market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include
Rising Prevalence of Genetic Diseases
. For instance, in the U.S., genetic diseases are the primary cause of newborn deaths, accounting for nearly 20% of annual infant mortality.
Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders
Technological Advancements fuels the Market Growth
For instance, in 2022, Thermo Fisher Scientific Inc., American supplier of scientific products, announced the launch of NGS-based test kit, which is a type of carrier screening approach in single solution that assists to scan the genetic disorders, including gene expression.
Market Segmentation
In terms of country, the United States is expected to be a lucrative market in the forecast period due to the increasing incidences of genetic conditions and technological advancements in the country.
Market Players
Eurofins Scientific, Inc., Fulgent Genetics, Inc., CENTOGENE N.V., Invitae Corporation, Illumina, Inc., Gene by Gene, Ltd., Laboratory Corporation of America Holdings, Natera, Inc., Myriad Genetics, Inc., and Quest Diagnostics, Inc
| Attribute | Details |
| Base Year | 2021 |
| Historic Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Type · Screening Type · Technology · Indication · End User · Company |
| Regional scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa; |
| Key companies profiled | Eurofins Scientific, Inc., Fulgent Genetics, Inc., CENTOGENE N.V., Invitae Corporation, Illumina, Inc., Gene by Gene, Ltd., Laboratory Corporation of America Holdings, Natera, Inc., Myriad Genetics, Inc., and Quest Diagnostics, Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |